Table 3.
Current clinical trials involving ruxolitinib combinations
| Drug 1 | Drug 2 | Phase | NCT number |
|---|---|---|---|
| Ruxolitinib | Decitabine | I/II | NCT02076191 |
| PRM-151 | II | NCT01981850 | |
| GS-6624 | II | NCT01369498 | |
| LDE225 | I/II | NCT01787552 | |
| PU-H71 | NCT03935555 | ||
| Navitoclax | II | NCT03222609 | |
| Umbralisib | I | NCT02493530 | |
| Parsaclisib | II | NCT02718300 | |
| PIM447 | Ib | NCT02370706 | |
| Itacitinib | II | NCT03144687 | |
| Pevonedistat | I | NCT03386214 | |
| Luspatercept | II | NCT03194542 | |
| Peg-interferonalpha-2a | I/II | NCT02742324 | |
| Sotatercept | |||
| vismodegib | Ib | NCT02593760 |